Clinical trials: FAPI PET
Pancreatic Ductal Adenocarcinoma (PDAC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal…
- Trial name
- FAPI-PRO (NCT07217717)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Cancer of Unknown Primary Site
FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary
This is a prospective single arm cohort study designed to evaluate the diagnostic ability of 68Ga-FAPI-PET/CT scan in determining likely tissue of origin in Cancer of Unknown Primary (CUP) patients not identified by standard of…
- Trial name
- FAPI-CUP (NCT05263700)
- Testing
- 68Ga-FAPi-46, PET/CT imaging
- Where
- 3 sites in Australia
- Volunteers
- 150 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer.
- Conditions
- Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma, Recurrent Prostate Carcinoma
- Trial name
- FAPI PET Prost (NCT04457232)
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Medullary Thyroid Cancer, Prositron Emission Tomography
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid…
- Conditions
- Medullary Thyroid Cancer, Prositron Emission Tomography, Fibroblast Activation Protein Inhibitor, Surgery
- Trial name
- NCT06277180
- Testing
- Surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
Positron Emission Tomography (PET) is a functional imaging technology for diagnosing and monitoring tumors. In clinical applications for malignant tumors, PET includes staging, response assessment, and prognosis prediction…
- Trial name
- NCT07128277
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Cancer
Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer
Cancer associated fibroblasts (CAFs) can promote tumor cell proliferation, migration, invasion, and angiogenesis through immunosuppressive effects and the production of mediators, thereby promoting tumor growth and progression.
- Trial name
- NCT06284070
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Endometriosis
The Role of FAPI PET-CT in Diagnosing Endometriosis
Patients with suspected endometriosis scheduled for surgery will be identified. They will be asked to participate in a study evaluating the feasibility of FAPI PET-CT in diagnosing endometriosis.
- Trial name
- NCT06792318
- Testing
- FAPI PET-CT
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Ziv Hospital
Prostate Cancer
Evaluation of Fapi-pet in Prostate Cancer.
The investigators explore the biodistribution of FAPI-PET expression in primary high-risk prostate cancer in men undergoing RALP and eLND and in men with metastatic PCa about to start next generation antiandrogen.
- Trial name
- FAPIPETPCA (NCT05192694)
- Testing
- Computed tomography
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Helsinki University Central Hospital
Heart Failure, Positron Emission Tomography
Visualized Monitoring of Fibrosis Formation in Heart Failure With 68GA-FAPI PET
This is a diagnostic study. Patients were included from patients with clinically suspected or confirmed heart failure, and 68Ga-FAPI and 13N-NH3 gated myocardial imaging were performed to evaluate the effectiveness of 68Ga-FAPI…
- Trial name
- NCT04982458
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Myositis, Idiopathic Inflammatory Myopathies
Characterizing Myositis With 68Ga-FAPI PET/CT
To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis and evaluation of systemic involvement in idiopathic inflammatory myopathies (IIM)/myositis, and compared the results with those of 18F-FDG PET/CT.
- Trial name
- NCT05952531
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Myelofibrosis
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic…
- Trial name
- NCT06164561
- Where
- China
- Volunteers
- 57 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
68Ga-FAPI, Ovarian Cancer
Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.
- Conditions
- 68Ga-FAPI, Ovarian Cancer, Epithelial Ovarian Cancer, Positron Emission Tomography
- Trial name
- NCT05856409
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Arthritis
Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease and inflammatory bowel disease.
- Trial name
- NCT04514614
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
FAP- Expressing Positive Tumors, RGD- Expressing Positive Tumors
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
FAP and RGD are overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-FAPI-RGD--a new dual-targeted 177Lu therapeutic drug…
- Trial name
- NCT06638034
- Testing
- 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in addition to routine diagnostic workup (including FDG PET/CT) at primary staging and restaging.
- Trial name
- NCT05903807
- Testing
- 68Ga-FAPi-46
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Aalborg University Hospital
Malignant Tumor, Positron Emission Tomography
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies.
- Conditions
- Malignant Tumor, Positron Emission Tomography, Fibroblast Activation Protein Inhibitor
- Trial name
- NCT06084767
- Testing
- 68Ga-TCR-FAPI PET/CT
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Neoplasm Female
Piloting 18F-FAPI PET/MRI for Applications in Breast Cancer
Breast cancer is the most common type of cancer in Norwegian women, with 4,224 new cases in 2022. More precise diagnosis are expected to result in more accurate assessment of treatment effect, and to contribute to both providing…
- Trial name
- NCT07180433
- Testing
- FAPI PET/MR
- Volunteers
- 60 people
- Sponsor
- St. Olavs Hospital
IgG4-Related Diseases
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
This study intends to use the new technology of fibroblast activation protein PET / CT to study whether the tiny residual lesions detected by 68Ga-FAPI PET / CT are related to the recurrence of IgG4-RD in patients with IgG4-RD…
- Trial name
- NCT07104058
- Testing
- 68Ga-FAPI PET / CT
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Luo Yaping
Inflammatory Bowel Disease
Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease.
- Trial name
- NCT04507932
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital